Trials / Recruiting
RecruitingNCT06796998
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Izidore Lossos, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Conditions
- Marginal Zone Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Splenic Marginal Zone Lymphoma
- Nodal Marginal Zone Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Epcoritamab | Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows: * Cycle 1, Day 1: 0.16 mg * Cycle 1, Day 8: 0.8 mg * Cycle 1, Day 15: 3 mg * Cycle 1, Day 22: 48 mg * Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg * Cycles 4 to 9, Days 1 and 15: 48 mg * Cycles 10 to 12; Day 1: 48 mg |
Timeline
- Start date
- 2025-10-13
- Primary completion
- 2028-10-15
- Completion
- 2031-04-15
- First posted
- 2025-01-28
- Last updated
- 2025-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06796998. Inclusion in this directory is not an endorsement.